Adam Crystal Sells 18,452 Shares of Tango Therapeutics (NASDAQ:TNGX) Stock

Tango Therapeutics, Inc. (NASDAQ:TNGX) insider Adam Crystal sold 18,452 shares of the company’s stock in a transaction that occurred on Tuesday, February 3rd. The shares were sold at an average price of $12.26, for a total transaction of $226,221.52. Following the transaction, the insider directly owned 187,218 shares in the company, valued at $2,295,292.68. The trade was a 8.97% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link.

Tango Therapeutics Stock Performance

Shares of TNGX opened at $11.95 on Friday. Tango Therapeutics, Inc. has a fifty-two week low of $1.03 and a fifty-two week high of $13.46. The company has a market capitalization of $1.61 billion, a PE ratio of -12.85 and a beta of 1.75. The stock has a fifty day moving average of $10.37 and a two-hundred day moving average of $8.55.

Tango Therapeutics (NASDAQ:TNGX) last announced its quarterly earnings data on Tuesday, November 4th. The company reported $0.13 EPS for the quarter, beating analysts’ consensus estimates of $0.01 by $0.12. The business had revenue of $53.81 million during the quarter, compared to the consensus estimate of $41.35 million. Tango Therapeutics had a negative return on equity of 60.80% and a negative net margin of 151.15%. As a group, equities research analysts forecast that Tango Therapeutics, Inc. will post -1.19 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms recently issued reports on TNGX. B. Riley raised their target price on shares of Tango Therapeutics from $8.00 to $14.00 and gave the stock a “buy” rating in a research report on Tuesday, November 18th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Tango Therapeutics in a research note on Monday, October 27th. Wall Street Zen upgraded shares of Tango Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, December 13th. Stifel Nicolaus began coverage on Tango Therapeutics in a report on Wednesday, December 3rd. They set a “buy” rating and a $15.00 price objective for the company. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Tango Therapeutics in a research report on Wednesday, January 21st. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Tango Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $13.60.

Hedge Funds Weigh In On Tango Therapeutics

Hedge funds have recently made changes to their positions in the business. Farallon Capital Management LLC boosted its position in Tango Therapeutics by 17.5% during the 3rd quarter. Farallon Capital Management LLC now owns 10,757,000 shares of the company’s stock worth $90,359,000 after purchasing an additional 1,600,000 shares during the period. Vanguard Group Inc. lifted its stake in shares of Tango Therapeutics by 33.6% during the fourth quarter. Vanguard Group Inc. now owns 6,750,977 shares of the company’s stock worth $59,814,000 after purchasing an additional 1,698,974 shares in the last quarter. Adage Capital Partners GP L.L.C. purchased a new stake in shares of Tango Therapeutics in the second quarter worth about $30,235,000. Balyasny Asset Management L.P. grew its stake in shares of Tango Therapeutics by 6.9% in the third quarter. Balyasny Asset Management L.P. now owns 3,472,207 shares of the company’s stock valued at $29,167,000 after buying an additional 224,744 shares in the last quarter. Finally, Nantahala Capital Management LLC grew its stake in shares of Tango Therapeutics by 15.1% in the second quarter. Nantahala Capital Management LLC now owns 3,439,594 shares of the company’s stock valued at $17,611,000 after buying an additional 451,611 shares in the last quarter. Hedge funds and other institutional investors own 78.99% of the company’s stock.

About Tango Therapeutics

Tango Therapeutics is a clinical-stage biotechnology company dedicated to developing precision medicines that exploit genetic vulnerabilities in cancer cells. Leveraging a proprietary synthetic lethality platform, the company identifies and targets tumor-specific dependencies in DNA damage response and related pathways. By focusing on tumor cell collateral sensitivities, Tango aims to bring differentiated small-molecule therapies to patients with genetic alterations that confer increased susceptibility to targeted inhibition.

The company’s lead pipeline comprises several early-stage programs, including inhibitors designed to selectively disable DNA repair proteins in tumor cells while sparing normal tissues.